Intelligence / Healthtech / De Novo Grants / DiaSorin, Inc.
DiaSorin, Inc.
23 Dec 2025: Novel device granted (FDA De Novo) · LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261). Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 23 Dec 2025
- Device
- LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261)
- Specialty
- Immunology
- Product Code
- SGW
- Country
- United States
- Location
- Stillwater, MN
- Submitted
- 2025-07-30
- Reference
- DEN250032
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Find the decision makers at DiaSorin, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for DiaSorin, Inc. in our registers.
More in Immunology
De Novo Grants
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.